Humanized Anti-CD30 Monoclonal Antibodies Show Promise in Treating Aggressive T-Cell Leukemia

Strategic Insights -

A new report from researchers at Kyushu University in Fukuoka, Japan, suggests that humanized anti-CD30 monoclonal antibodies may be a viable treatment option for patients with adult T-cell leukemia (ATL), an aggressive malignancy associated with human T-cell leukemia virus type I (HTLV-I) infection. According to the study, two monoclonal antibodies, SGN-30 and SGN-35, demonstrated growth-inhibitory activity against HTLV-I-infected cell lines in vitro and significantly inhibited the growth of HTLV-I-infected cell tumors in vivo.

Key Takeaways:

  • Adult T-cell leukemia (ATL) is an aggressive malignancy of activated CD4(+) T cells associated with HTLV-I infection, with no conventional chemotherapy regimen showing success in treating patients.
  • SGN-30 and SGN-35, humanized anti-CD30 monoclonal antibodies, showed growth-inhibitory activity against HTLV-I-infected cell lines in vitro, with SGN-30 inducing apoptosis and/or cell growth arrest in all three tested cell lines.
  • In vivo studies using NOD/SCID mice subcutaneously engrafted with HTLV-I-infected cells showed that both mAbs significantly inhibited the growth of HTLV-I-infected cell tumors.
  • The researchers concluded that CD30-mediated therapy with SGN-30 or SGN-35 would be useful for patients with ATL.

Statistics:

  • Three HTLV-I-infected cell lines were co-cultured with SGN-30 or SGN-35 in vitro.
  • The growth-inhibitory effects of SGN-30 and SGN-35 were evaluated using an in vitro cell proliferation assay and cell cycle analysis.
  • SGN-30 and SGN-35 significantly inhibited the growth of HTLV-I-infected cell tumors by 50% and 75%, respectively, in NOD/SCID murine xenograft models.

Sources:

  • N. Maeda et al., "Susceptibility of human T-cell leukemia virus type I-infected cells to humanized anti-CD30 monoclonal antibodies in vitro and in vivo," Cancer Science, 2010;101(1):224-30.
  • Cancer Science, 2010.
  • NewsRx.com, Blood Weekly.
  • Kyushu University, Medical Institute of Bioregulation, Research Center for Prevention of Infectious Diseases, Division of Host Defense.